Chiffres calculés à partir des déclarations réglementaires officielles — .
Détentioninitiés 0% · institutions 0.02% · vente à découvert 3.5% du flottant
En USD · au Oct 19, 2026
Interroger la machine
Recherchez et comparez les opérations d’initiés, les sociétés et leurs statistiques en langage courant. Votre question devient une requête sur les données disponibles, pas une conversation ni un conseil en investissement.
Données de GLOBEIMMUNE INC uniquement. Pas de recherche web. Les statistiques globales d’un initié sont exclues.
Une recherche exécutée consomme un crédit, même sans résultat. Les erreurs et les questions non prises en charge ne consomment rien.
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platforms. The company's product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado. GlobeImmune, Inc. operates as a subsidiary of NantCell, Inc.
Source des informations de marché · Oct 19, 2026
Identité selon la SEC · Oct 19, 2026
Chronologie sur le marché · historique complet
7 achats79 ventes— cours de clôturebarre = volume usd, échelle √cliquez sur une période pour filtrer le tableau
| Initié | Type | Valeur · USD | Signaux | Détail | |
|---|---|---|---|---|---|
| Torres S. Edward | Vente | $43.7K | SEC | ||
| MITCHELL DANIEL J |
| Vente |
| $16.4K |
| SEC |
| MITCHELL DANIEL Jhistorique | Vente | $19K | SEC |
| MITCHELL DANIEL Jhistorique | Vente | $240.2 | SEC |
| LAWLOR AUGUSTINEhistorique | Vente | $17.1K | SEC |
| MITCHELL DANIEL Jhistorique | Vente | $207.2 | SEC |
| LAWLOR AUGUSTINEhistorique | Vente | $5.1K | SEC |
| MITCHELL DANIEL Jhistorique | Vente | $177.9K | Taille inhabituelle | SEC |
| MITCHELL DANIEL Jhistorique | Vente | $4.9K | SEC |
| MITCHELL DANIEL Jhistorique | Vente | $1.4K | SEC |
| MITCHELL DANIEL Jhistorique | Vente | $110.3K | Taille inhabituelle | SEC |
| LAWLOR AUGUSTINEhistorique | Vente | $270 | SEC |
| LAWLOR AUGUSTINEhistorique | Vente | $26.1K | SEC |
| MITCHELL DANIEL Jhistorique | Vente | $147.3 | SEC |
| MITCHELL DANIEL Jhistorique | Vente | $6.5K | SEC |
| MITCHELL DANIEL Jhistorique | Vente | $190 | SEC |
| MITCHELL DANIEL Jhistorique | Vente | $5.3K | SEC |
| MITCHELL DANIEL Jhistorique | Vente | $181.3 | SEC |
| MITCHELL DANIEL Jhistorique | Vente | $6.8K | SEC |
| LAWLOR AUGUSTINEhistorique | Vente | $5.3K | SEC |
| LAWLOR AUGUSTINEhistorique | Vente | $5.5K | SEC |
| LAWLOR AUGUSTINEhistorique | Vente | $5K | SEC |
| MITCHELL DANIEL Jhistorique | Vente | $179.5 | SEC |
| MITCHELL DANIEL Jhistorique | Vente | $51.5 | SEC |
| MITCHELL DANIEL Jhistorique | Vente | $1.9K | SEC |